{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T05:01:38Z","timestamp":1789275698367,"version":"build-2803163510"},"reference-count":138,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T00:00:00Z","timestamp":1787443200000},"content-version":"am","delay-in-days":387,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.blre.2025.101301","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T10:55:31Z","timestamp":1747220131000},"page":"101301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Navigating the dynamic landscape of lower-risk MDS: Advances and emerging insights"],"prefix":"10.1016","volume":"73","author":[{"given":"Alain","family":"Mina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazan","family":"Madanat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Abaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.blre.2025.101301_bb0005","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2025.101301_bb0010","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.blre.2025.101301_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.blre.2018.09.001","article-title":"Epidemiology of myelodysplastic syndromes: why characterizing the beast is a prerequisite to taming it","volume":"34","author":"Zeidan","year":"2019","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.blre.2025.101301_bb0020","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/hematology.2023000520","article-title":"Next-generation therapy for lower-risk MDS","volume":"2023","author":"S\u00e9bert","year":"2023","journal-title":"Hematology"},{"key":"10.1016\/j.blre.2025.101301_bb0025","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/S0145-2126(07)70197-2","article-title":"Prospective cross-sectional analysis of cytopenias and transfusion needs of MDS patients in the United States","volume":"31","author":"Sekeres","year":"2007","journal-title":"Leuk Res"},{"issue":"5","key":"10.1016\/j.blre.2025.101301_bb0030","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.blre.2018.03.002","article-title":"To chelate or not to chelate in MDS: that is the question!","volume":"32","author":"Zeidan","year":"2018","journal-title":"Blood Rev"},{"issue":"11","key":"10.1016\/j.blre.2025.101301_bb0035","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1080\/14737140.2024.2414071","article-title":"Targeted therapies for myelodysplastic syndromes\/neoplasms (MDS): current landscape and future directions","volume":"24","author":"Bidikian","year":"2024","journal-title":"Expert Rev Anticancer Ther"},{"issue":"4","key":"10.1016\/j.blre.2025.101301_bb0040","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1586\/17474086.2013.814456","article-title":"Iron chelation therapy in myelodysplastic syndromes: where do we stand?","volume":"6","author":"Mitchell","year":"2013","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"10.1016\/j.blre.2025.101301_bb0045","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00277-018-3539-7","article-title":"Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes","volume":"98","author":"Zeidan","year":"2019","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.blre.2025.101301_bb0050","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2217\/cer.15.20","article-title":"Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes","volume":"4","author":"Zeidan","year":"2015","journal-title":"J Comp Eff Res"},{"issue":"14","key":"10.1016\/j.blre.2025.101301_bb0055","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1182\/blood-2011-07-369009","article-title":"Lenalidomide in MDS: 4th time\u2019s a charm","volume":"118","author":"Sekeres","year":"2011","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.blre.2025.101301_bb0060","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1002\/cncr.30903","article-title":"A call for action: increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials","volume":"123","author":"Zeidan","year":"2017","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.blre.2025.101301_bb0065","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.69","article-title":"Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes\/neoplasms (MDS): practical considerations from the international consortium for MDS (icMDS)","volume":"8","author":"Efficace","year":"2024","journal-title":"Hemasphere"},{"key":"10.1016\/j.blre.2025.101301_bb0070","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/bloodadvances.2024014865","article-title":"Advancing drug development in myelodysplastic syndromes","volume":"9","author":"Mina","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101301_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101128","article-title":"Classification, risk stratification and response assessment in myelodysplastic syndromes\/neoplasms (MDS): a state-of-the-art report on behalf of the international consortium for MDS (icMDS)","volume":"62","author":"Stahl","year":"2023","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.blre.2025.101301_bb0080","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrc.2016.112","article-title":"The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia","volume":"17","author":"Sperling","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"7290","key":"10.1016\/j.blre.2025.101301_bb0085","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nature08851","article-title":"Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia","volume":"464","author":"Raaijmakers","year":"2010","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.blre.2025.101301_bb0090","doi-asserted-by":"crossref","first-page":"6735","DOI":"10.1158\/1078-0432.CCR-07-4843","article-title":"The Interleukin-8 pathway in Cancer","volume":"14","author":"Waugh","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2025.101301_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2021.102090","article-title":"Personal history of autoimmune disease and other medical conditions and risk of myelodysplastic syndromes","volume":"76","author":"Linabery","year":"2022","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"10.1016\/j.blre.2025.101301_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2024.101537","article-title":"Germline predisposition to myeloid neoplasms: characteristics and management of high versus variable penetrance disorders","volume":"37","author":"Trottier","year":"2024","journal-title":"Best Pract Res Clin Haematol"},{"issue":"2","key":"10.1016\/j.blre.2025.101301_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2021.101280","article-title":"Biology and clinical management of hypoplastic MDS: MDS as a bone marrow failure syndrome","volume":"34","author":"Karantanos","year":"2021","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"10.1016\/j.blre.2025.101301_bb0110","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/asheducation-2017.1.453","article-title":"Current treatment algorithm for the management of lower-risk MDS","volume":"2017","author":"Giagounidis","year":"2017","journal-title":"Hematology"},{"key":"10.1016\/j.blre.2025.101301_bb0115","first-page":"2157","article-title":"Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia","volume":"109","author":"Jain","year":"2024","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.blre.2025.101301_bb0120","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1001\/jama.1953.03690110032010","article-title":"Preleukemic acute human leukemia","volume":"152","author":"Block","year":"1953","journal-title":"JAMA: JAMA"},{"issue":"26","key":"10.1016\/j.blre.2025.101301_bb0125","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1182\/blood.2023020078","article-title":"Diagnosis and classification of myelodysplastic syndromes","volume":"142","author":"Hasserjian","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2025.101301_bb0130","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Bennett","year":"1982","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2025.101301_bb0135","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11899-006-0011-x","article-title":"WHO is WHO in myelodysplastic syndromes? Clinical implications of the WHO classification","volume":"1","author":"Komrokji","year":"2006","journal-title":"Curr Hematol Malig Rep"},{"issue":"5","key":"10.1016\/j.blre.2025.101301_bb0140","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.blre.2025.101301_bb0145","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2025.101301_bb0150","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.3390\/genes12081144","article-title":"The genetics of myelodysplastic syndromes: clinical relevance","volume":"12","author":"Chiereghin","year":"2021","journal-title":"Genes (Basel)"},{"issue":"7","key":"10.1016\/j.blre.2025.101301_bb0155","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.blre.2025.101301_bb0160","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2025.101301_bb0165","doi-asserted-by":"crossref","first-page":"e862","DOI":"10.1016\/S2352-3026(24)00251-5","article-title":"Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the international consortium for myelodysplastic syndromes","volume":"11","author":"Komrokji","year":"2024","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.blre.2025.101301_bb0170","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1038\/s41375-018-0173-2","article-title":"Diagnostic algorithm for lower-risk myelodysplastic syndromes","volume":"32","author":"Mufti","year":"2018","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.blre.2025.101301_bb0175","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.3390\/diagnostics12071590","article-title":"VEXAS syndrome: a novelty in MDS landscape","volume":"12","author":"Templ\u00e9","year":"2022","journal-title":"Diagnostics"},{"issue":"4","key":"10.1016\/j.blre.2025.101301_bb0180","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11899-013-0172-3","article-title":"There\u2019s risk, and then there\u2019s RISK: the latest clinical prognostic risk stratification models in myelodysplastic syndromes","volume":"8","author":"Zeidan","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"10.1016\/j.blre.2025.101301_bb0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.blre.2015.06.004","article-title":"The evolving field of prognostication and risk stratification in MDS: recent developments and future directions","volume":"30","author":"Lee","year":"2016","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2025.101301_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100689","article-title":"Therapeutic strategies in low and high-risk MDS: what does the future have to offer?","volume":"45","author":"Scalzulli","year":"2021","journal-title":"Blood Rev"},{"issue":"6","key":"10.1016\/j.blre.2025.101301_bb0195","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.blre.2025.101301_bb0200","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2006.08.5696","article-title":"Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes","volume":"25","author":"Malcovati","year":"2007","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1016\/j.blre.2025.101301_bb0205","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.20.02810","article-title":"Personalized prediction model to risk stratify patients with myelodysplastic syndromes","volume":"39","author":"Nazha","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.blre.2025.101301_bb0210","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1200\/JCO.20.01659","article-title":"Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes","volume":"39","author":"Bersanelli","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2025.101301_bb0215","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1016\/S2352-3026(22)00323-4","article-title":"A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study","volume":"10","author":"Maggioni","year":"2023","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.blre.2025.101301_bb0220","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/s41375-023-01831-1","article-title":"Risk prediction in MDS: independent validation of the IPSS-M\u2014ready for routine?","volume":"37","author":"Baer","year":"2023","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.blre.2025.101301_bb0225","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO.22.01784","article-title":"Real-world validation of molecular international prognostic scoring system for myelodysplastic syndromes","volume":"41","author":"Sauta","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.blre.2025.101301_bb0230","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1182\/blood-2016-02-700054","article-title":"Time-dependent changes in mortality and transformation risk in MDS","volume":"128","author":"Pfeilst\u00f6cker","year":"2016","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.blre.2025.101301_bb0235","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1182\/blood.2023023005","article-title":"How I reduce and treat posttransplant relapse of MDS","volume":"143","author":"Mina","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101301_bb0240","series-title":"The effect of transfusion dependency and secondary iron overload on survival of patients with myelodysplastic syndrome. ASH annual meeting abstracts 106","first-page":"791","author":"Malcovati","year":"2005"},{"issue":"12","key":"10.1016\/j.blre.2025.101301_bb0245","first-page":"3671","article-title":"Report of an international working group to standardize response criteria for myelodysplastic syndromes","volume":"96","author":"Cheson","year":"2000","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2025.101301_bb0250","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the international working group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2025.101301_bb0255","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1182\/blood-2018-06-857102","article-title":"Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials","volume":"133","author":"Platzbecker","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2025.101301_bb0260","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1046\/j.1365-2141.1997.4013211.x","article-title":"Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model","volume":"99","author":"Hellstr\u00f6m-Lindberg","year":"1997","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.blre.2025.101301_bb0265","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/ajh.24842","article-title":"ITACA: a new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems","volume":"92","author":"Buckstein","year":"2017","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.blre.2025.101301_bb0270","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1038\/s41375-018-0118-9","article-title":"A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-\u03b1 in anemic patients with low-risk MDS","volume":"32","author":"Fenaux","year":"2018","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.blre.2025.101301_bb0275","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1038\/leu.2017.192","article-title":"A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes","volume":"31","author":"Platzbecker","year":"2017","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101301_bb0280","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1182\/blood-2024-194510","article-title":"Early versus late onset of ESA in lower risk anemic MDS patients: results of the GFM randomized phase III EPO-Pretar trial","volume":"144","author":"Park","year":"2024","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2025.101301_bb0285","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/cncr.28663","article-title":"Results of a randomized, double-blind study of romiplostim versus placebo in patients with low\/intermediate-1\u2013risk myelodysplastic syndrome and thrombocytopenia","volume":"120","author":"Giagounidis","year":"2014","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.blre.2025.101301_bb0290","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1016\/S2352-3026(18)30016-4","article-title":"Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial","volume":"5","author":"Kantarjian","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2025.101301_bb0295","first-page":"2519","article-title":"Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms \u2013 results of the EUROPE trial by EMSCO","volume":"36","author":"Kubasch","year":"2022","journal-title":"Leukemia"},{"issue":"28","key":"10.1016\/j.blre.2025.101301_bb0300","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1200\/JCO.22.02699","article-title":"Eltrombopag for low-risk myelodysplastic syndromes with thrombocytopenia: interim results of a phase II, randomized, placebo-controlled clinical trial (EQOL-MDS)","volume":"41","author":"Oliva","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.blre.2025.101301_bb0305","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/sj.leu.2403806","article-title":"Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution","volume":"19","author":"Bernasconi","year":"2005","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.blre.2025.101301_bb0310","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/sj.leu.2403189","article-title":"Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31","volume":"18","author":"Giagounidis","year":"2004","journal-title":"Leukemia"},{"issue":"5474","key":"10.1016\/j.blre.2025.101301_bb0315","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/251437a0","article-title":"Distinct haematological disorder with deletion of long arm of no. 5 chromosome","volume":"251","author":"Van Den Berghe","year":"1974","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.blre.2025.101301_bb0320","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.blre.2025.101301_bb0325","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa041668","article-title":"Efficacy of lenalidomide in myelodysplastic syndromes","volume":"352","author":"List","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2025.101301_bb0330","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1182\/blood-2007-01-068833","article-title":"Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1\u2013risk myelodysplastic syndromes with karyotypes other than deletion 5q","volume":"111","author":"Raza","year":"2008","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.blre.2025.101301_bb0335","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2011-01-330126","article-title":"A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-\/Intermediate-1-risk myelodysplastic syndromes with del5q","volume":"118","author":"Fenaux","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2025.101301_bb0340","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1038\/s41375-018-0029-9","article-title":"A decade of progress in myelodysplastic syndrome with chromosome 5q deletion","volume":"32","author":"List","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.blre.2025.101301_bb0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-013-1863-5","article-title":"Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes","volume":"93","author":"Giagounidis","year":"2014","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.blre.2025.101301_bb0350","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjh.12203","article-title":"<scp>TP<\/scp> 53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis","volume":"160","author":"Kulasekararaj","year":"2013","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2025.101301_bb0355","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.3324\/haematol.2017.181404","article-title":"Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide","volume":"103","author":"Lod\u00e9","year":"2018","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.blre.2025.101301_bb0360","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/leu.2011.95","article-title":"The role of Smad signaling in hematopoiesis and translational hematology","volume":"25","author":"Blank","year":"2011","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.blre.2025.101301_bb0365","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/s41375-019-0420-1","article-title":"The role of TGF\u03b2 in hematopoiesis and myeloid disorders","volume":"33","author":"Bataller","year":"2019","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.blre.2025.101301_bb0370","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1182\/blood-2008-02-139824","article-title":"Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS","volume":"112","author":"Zhou","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2025.101301_bb0375","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.41","article-title":"Luspatercept: a peaceful revolution in the standard of care for myelodysplastic neoplasms","volume":"8","author":"Vinchi","year":"2024","journal-title":"Hemasphere"},{"issue":"10","key":"10.1016\/j.blre.2025.101301_bb0380","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S1470-2045(17)30615-0","article-title":"Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study","volume":"18","author":"Platzbecker","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.blre.2025.101301_bb0385","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101301_bb0390","doi-asserted-by":"crossref","first-page":"6971","DOI":"10.1182\/blood-2022-157487","article-title":"Multiple Episodes of Transfusion Independence with Luspatercept Treatment and the Impact of Dose Escalation in Patients with Lower-Risk Myelodysplastic Syndromes from the MEDALIST Study","volume":"140","author":"Platzbecker","year":"2022","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2025.101301_bb0395","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000616","article-title":"The European medicines agency review of Luspatercept for the treatment of adult patients with transfusion-dependent Anemia caused by low-risk myelodysplastic syndromes with ring Sideroblasts or Beta-thalassemia","volume":"5","author":"Delgado","year":"2021","journal-title":"Hemasphere"},{"issue":"20","key":"10.1016\/j.blre.2025.101301_bb0400","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1182\/blood.2022016171","article-title":"Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts","volume":"140","author":"Zeidan","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2025.101301_bb0405","doi-asserted-by":"crossref","first-page":"e646","DOI":"10.1016\/S2352-3026(24)00203-5","article-title":"Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial","volume":"11","author":"Della Porta","year":"2024","journal-title":"Lancet Haematol"},{"issue":"10423","key":"10.1016\/j.blre.2025.101301_bb0410","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(23)01724-5","article-title":"Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"403","author":"Platzbecker","year":"2024","journal-title":"Lancet"},{"issue":"2.5","key":"10.1016\/j.blre.2025.101301_bb0415","volume":"22","author":"Madanat","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"issue":"S3","key":"10.1016\/j.blre.2025.101301_bb0420","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000969832.59030.29","article-title":"P732: analysis of patient-reported fatigue in imerge PH3 trial of imetelstat vs placebo in heavily transfused non-del(5Q) lower-risk myelodysplastic syndromes r\/r to erythropoiesis stimulating agents","volume":"7","author":"Sekeres","year":"2023","journal-title":"Hemasphere"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101301_bb0425","volume":"142","author":"Komrokji","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2025.101301_bb0430","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.3324\/haematol.2012.063420","article-title":"Infections in myelodysplastic syndromes","volume":"97","author":"Toma","year":"2012","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.blre.2025.101301_bb0435","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1053\/j.seminhematol.2024.07.004","article-title":"Infections and antimicrobial prophylaxis in patients with myelodysplastic syndromes","volume":"61","author":"Czech","year":"2024","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2025.101301_bb0440","first-page":"1079a","article-title":"Randomized trial of subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF) versus observation in patients (pts) with myelodysplastic syndrome (MDS)","volume":"116","author":"Schuster","year":"1990","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"10.1016\/j.blre.2025.101301_bb0445","first-page":"196a","article-title":"Phase III randomized multicenter trial of recombinant human G-CSF in MDS","volume":"82","author":"Greenberg","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101301_bb0455","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0145-2126(07)70459-9","article-title":"Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes","volume":"31","author":"Malcovati","year":"2007","journal-title":"Leuk Res"},{"issue":"8","key":"10.1016\/j.blre.2025.101301_bb0460","doi-asserted-by":"crossref","first-page":"513","DOI":"10.7326\/M19-0916","article-title":"Iron chelation in transfusion-dependent patients with low- to Intermediate-1-risk myelodysplastic syndromes: a randomized trial","volume":"172","author":"Angelucci","year":"2020","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.blre.2025.101301_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2022.101405","article-title":"How can we improve response assessments in MDS? Strategies to improve response assessment in MDS treatment paradigms","volume":"35","author":"Bejar","year":"2022","journal-title":"Best Pract Res Clin Haematol"},{"issue":"3","key":"10.1016\/j.blre.2025.101301_bb0480","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/PPO.0000000000000666","article-title":"Evolution of therapeutic benefit measurement criteria in myelodysplastic syndromes\/neoplasms","volume":"29","author":"Stempel","year":"2025","journal-title":"Cancer J"},{"issue":"4","key":"10.1016\/j.blre.2025.101301_bb0485","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.3324\/haematol.2022.281856","article-title":"Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes","volume":"108","author":"Zeidner","year":"2022","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.blre.2025.101301_bb0490","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1053\/j.seminhematol.2024.10.010","article-title":"Patient-reported outcomes in early phase trials for patients with myelodysplastic syndromes","volume":"61","author":"Mendoza","year":"2024","journal-title":"Semin Hematol"},{"issue":"5","key":"10.1016\/j.blre.2025.101301_bb0495","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.blre.2025.101301_bb0500","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3324\/haematol.2015.140335","article-title":"Prospective international validation of the quality of life in myelodysplasia scale (QUALMS)","volume":"101","author":"Abel","year":"2016","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.blre.2025.101301_bb0505","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101301_bb0510","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-113167","article-title":"Longitudinal sensitivity of the MD Anderson symptom inventory for acute myeloid leukemia","volume":"132","author":"Williams","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2025.101301_bb0515","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"106","author":"Basch","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.blre.2025.101301_bb0520","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1182\/bloodadvances.2023010098","article-title":"Towards a conceptualization of measurable residual disease in myelodysplastic syndromes","volume":"7","author":"Schulz","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101301_bb0525","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/bloodadvances.2024014865","article-title":"Advancing drug development in myelodysplastic syndromes","volume":"9","author":"Mina","year":"2025","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.blre.2025.101301_bb0530","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of Azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2025.101301_bb0535","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.blre.2025.101301_bb0540","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.blre.2025.101301_bb0545","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41598-019-56642-1","article-title":"Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study","volume":"10","author":"Lee","year":"2020","journal-title":"Sci Rep"},{"issue":"20","key":"10.1016\/j.blre.2025.101301_bb0550","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1200\/JCO.2012.44.6823","article-title":"Randomized open-label phase II study of Decitabine in patients with low- or intermediate-risk myelodysplastic syndromes","volume":"31","author":"Garcia-Manero","year":"2013","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.blre.2025.101301_bb0555","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1200\/JCO.2010.34.4226","article-title":"Phase I study of Oral Azacitidine in myelodysplastic syndromes, chronic Myelomonocytic leukemia, and acute myeloid leukemia","volume":"29","author":"Garcia-Manero","year":"2011","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.blre.2025.101301_bb0560","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200034","article-title":"Low-dose Decitabine versus low-dose Azacitidine in lower-risk MDS","volume":"1","author":"Sasaki","year":"2022","journal-title":"NEJM Evid"},{"issue":"2","key":"10.1016\/j.blre.2025.101301_bb0565","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/ajh.26771","article-title":"A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes","volume":"98","author":"Zeidan","year":"2023","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.blre.2025.101301_bb0570","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/MOH.0000000000000016","article-title":"Beyond hypomethylating agents failure in patients with myelodysplastic syndromes","volume":"21","author":"Zeidan","year":"2014","journal-title":"Curr Opin Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101301_bb0575","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-203612","article-title":"Effect of prior treatments on the clinical activity of Imetelstat in transfusion-dependent patients with erythropoiesis-stimulating agent, relapsed or refractory\/ineligible lower-risk myelodysplastic syndromes","volume":"144","author":"Platzbecker","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101301_bb0580","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-178689","article-title":"Impact of genomic landscape and mutational burden on primary endpoint responses in the COMMANDS study","volume":"142","author":"Komrokji","year":"2023","journal-title":"Blood"},{"issue":"10399","key":"10.1016\/j.blre.2025.101301_bb0585","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0140-6736(23)00874-7","article-title":"Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial","volume":"402","author":"Platzbecker","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2025.101301_bb0590","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood.2024025702","article-title":"Imetelstat: a new addition to the therapeutic landscape of lower-risk MDS","volume":"145","author":"Abaza","year":"2024","journal-title":"Blood J"},{"issue":"5","key":"10.1016\/j.blre.2025.101301_bb0595","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.leukres.2012.01.006","article-title":"The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes","volume":"36","author":"Platzbecker","year":"2012","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.blre.2025.101301_bb0600","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/s41375-018-0089-x","article-title":"Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study","volume":"32","author":"Stauder","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.blre.2025.101301_bb0605","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/01.CIR.0000134279.79571.73","article-title":"Anemia and its relationship to clinical outcome in heart failure","volume":"110","author":"Anand","year":"2004","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.blre.2025.101301_bb0610","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3324\/haematol.2018.212217","article-title":"Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes","volume":"105","author":"de Swart","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.blre.2025.101301_bb0615","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000445163","article-title":"Association between transfusion status and overall survival in patients with myelodysplastic syndromes: a systematic literature review and Meta-analysis","volume":"136","author":"Harnan","year":"2016","journal-title":"Acta Haematol"},{"issue":"9","key":"10.1016\/j.blre.2025.101301_bb0620","doi-asserted-by":"crossref","first-page":"e659","DOI":"10.1016\/S2352-3026(24)00142-X","article-title":"Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial","volume":"11","author":"D\u00edez-Campelo","year":"2024","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101301_bb0625","article-title":"The ELEMENT-MDS trial: a phase 3 randomized study evaluating Luspatercept versus Epoetin alfa in erythropoiesis-stimulating agent-naive, non-transfusion-dependent","volume":"142","author":"Zeidan","year":"2023","journal-title":"Lower-Risk Myelodysplastic Syndromes Blood"},{"issue":"14","key":"10.1016\/j.blre.2025.101301_bb0630","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1182\/bloodadvances.2023009781","article-title":"Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes","volume":"7","author":"Komrokji","year":"2023","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101301_bb0635","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-204791","article-title":"Combining ESA and Luspatercept in non-RS MDS patients having failed ESA - results of the phase 1-2 part a of the GFM Combola study","volume":"144","author":"Ades","year":"2024","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.blre.2025.101301_bb0640","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12134217","article-title":"Iron parameters in patients treated with Roxadustat for Anemia of chronic kidney disease","volume":"12","author":"Ganz","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.blre.2025.101301_bb0645","author":"Astellas Pharma Europe B.V"},{"issue":"2","key":"10.1016\/j.blre.2025.101301_bb0650","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/ajh.26397","article-title":"Roxadustat for the treatment of anemia in patients with <scp>lower-risk<\/scp> myelodysplastic syndrome: open-label, dose-selection, lead-in stage of a phase 3 study","volume":"97","author":"Henry","year":"2022","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.blre.2025.101301_bb0655","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/ajh.27410","article-title":"Roxadustat versus placebo for patients with lower-risk myelodysplastic syndrome: MATTERHORN phase 3, double-blind, randomized controlled trial","volume":"99","author":"Mittelman","year":"2024","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.blre.2025.101301_bb0660","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1038\/s41375-023-01949-2","article-title":"Activation of distinct inflammatory pathways in subgroups of LR-MDS","volume":"37","author":"Schneider","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2025.101301_bb0665","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-198326","article-title":"Preliminary safety and biomarker results of the NLRP3 Inflammasome inhibitor DFV890 in adult patients with myeloid diseases: a phase 1b study","volume":"144","author":"Garcia-Manero","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101301_bb0670","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-206096","article-title":"R289, a dual Irak 1\/4 inhibitor, in patients with relapsed\/refractory (R\/R) lower-risk myelodysplastic syndrome (LR-MDS): initial results from a phase 1b study","volume":"144","author":"Garcia-Manero","year":"2024","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.blre.2025.101301_bb0675","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1056\/NEJMra1904794","article-title":"Myelodysplastic syndromes","volume":"383","author":"Cazzola","year":"2020","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.blre.2025.101301_bb0680","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1182\/blood-2017-01-763425","article-title":"Clinical significance of somatic mutation in unexplained blood cytopenia","volume":"129","author":"Malcovati","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2025.101301_bb0685","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(19)30211-X","article-title":"Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states","volume":"7","author":"Gondek","year":"2020","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.blre.2025.101301_bb0690","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1182\/bloodadvances.2020003976","article-title":"Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients","volume":"5","author":"Li","year":"2021","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101301_bb0695","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-203837","article-title":"High-risk Ccus is clinically indistinguishable from low-risk myelodysplastic syndromes\/neoplasms","volume":"144","author":"Xie","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2025.101301_bb0700","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200310","article-title":"Prediction of risk for myeloid malignancy in clonal hematopoiesis","volume":"2","author":"Weeks","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.blre.2025.101301_bb0705","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101072","article-title":"Current landscape of translational and clinical research in myelodysplastic syndromes\/neoplasms (MDS): proceedings from the 1st international workshop on MDS (iwMDS) of the international consortium for MDS (icMDS)","volume":"60","author":"Bewersdorf","year":"2023","journal-title":"Blood Rev"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T18:07:09Z","timestamp":1762279629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X25000463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":138,"alternative-id":["S0268960X25000463"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2025.101301","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Navigating the dynamic landscape of lower-risk MDS: Advances and emerging insights","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2025.101301","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101301"}}